Business
Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day
Company announces strong long-range financial outlook for 2025–2028 Introduces next-generation innovation pipeline to transform diabetes care ACTON,
About this update from Insulet Corporation
[{"type":"text","content":"\n\nCompany announces strong long-range financial outlook for 2025–2028\n\n\n\nIntroduces next-generation innovation pipeline to transform diabetes care \n\n\n\n ACTON, Mass.--(BUSINESS WIRE)--\nInsulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company’s global headquarters in Acton, Massachusetts.\n\n\nDuring the event, Insulet’s executive team outlined the strategic plan and innovation roadmap that is designed to extend its leadership in the fast-growing and significantly underpenetrated global markets for automated insulin delivery (AID) for type 1 and type 2 diabetes, as well as its financial outlook for 2025-2028. Insulet is focused on driving growth within its $30 billion-plus total addressable market by accelerating innovation, advancing clinical practice, expanding access, and generating demand through commercial excellence. Executives also detailed the Company’s deep and defensible competitive moats and strategic advantages, including its unique form factor, pay-as-you-go pharmacy model, highly advanced automated manufacturing and supply chain, leading brand, and strong financial position.\n\n\n“Insulet’s success has always been rooted in one simple conviction: there has to be a better way,” said Ashley McEvoy, President and Chief Executive Officer. “That belief drives every breakthrough, every investment, and every decision we make – from transforming insulin delivery to reimagining how people access care. It’s powered our evolution from a disruptive startup to a global market leader, and today it fuels our next chapter of growth and impact as we outline a clear strategy to expand our reach and deliver on our mission to transform life for people with diabetes.”\n\n\n2025–2028 Financial Outlook\n\n\n\nRevenue: Projected to grow at a compound annual growth rate (CAGR) of approximately 20% at constant currency rates, driven by continued Omnipod adoption and geographic expansion.\n\n\n\nAdjusted Operating Margin: Expected to expand annually by approximately 100 basis points, reflecting operational efficiencies and growing scale.\n\n\n\nAdjusted Diluted Earnings Per Share: Anticipated to grow at a CAGR of 25%+, underscoring the Company’s commitment to profitable growth.\n\n\n\nF...